This strategy is nicely reflected by the recent attempts of treating HCC by the PD-1 checkpoint inhibitor nivolumab, that among others target CD8+ T cells, led to tumor reduction and to a sustained objective response in 15–20% of patients with advanced HCC [32]. The gene discussed is CD8A; the disease is neoplasm.